MX2009002708A - Nuevos derivados de tipo benzofurano, una composicion que comprende los mismos para tratar o prevenir la disfuncion cognitiva y el uso de los mismos. - Google Patents

Nuevos derivados de tipo benzofurano, una composicion que comprende los mismos para tratar o prevenir la disfuncion cognitiva y el uso de los mismos.

Info

Publication number
MX2009002708A
MX2009002708A MX2009002708A MX2009002708A MX2009002708A MX 2009002708 A MX2009002708 A MX 2009002708A MX 2009002708 A MX2009002708 A MX 2009002708A MX 2009002708 A MX2009002708 A MX 2009002708A MX 2009002708 A MX2009002708 A MX 2009002708A
Authority
MX
Mexico
Prior art keywords
treating
composition
same
preventing cognitive
cognitive dysfunction
Prior art date
Application number
MX2009002708A
Other languages
English (en)
Inventor
Dong Wook Kang
Jee Woo Lee
Young Ho Kim
Hee Kim
Hee Jin Ha
Eun Joo Nam
Cha Mi Joung
Original Assignee
Digital Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Digital Biotech Co Ltd filed Critical Digital Biotech Co Ltd
Publication of MX2009002708A publication Critical patent/MX2009002708A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con los nuevos derivados de benzofurano, la preparación de los mismos y la composición que los comprende. Los derivados de benzofurano de la presente invención mostraron una potente actividad de inhibición de la agregación beta-amiloide y la citotoxicidad celular resultando en la estimulación de la proliferación de las células neuronales, así como la recuperación de la actividad de aprendizaje de la memoria dañada provocado por el daño celular neuronal usando un modelo animal transformado con genes precursores beta-amiloide, por lo tanto, los compuestos pueden ser útiles en el tratamiento o prevención del trastorno de la función cognitiva.
MX2009002708A 2006-10-02 2007-10-02 Nuevos derivados de tipo benzofurano, una composicion que comprende los mismos para tratar o prevenir la disfuncion cognitiva y el uso de los mismos. MX2009002708A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020060097388A KR100858357B1 (ko) 2006-10-02 2006-10-02 벤조퓨란계 유도체 화합물을 유효성분으로 함유하는인지기능 장애의 예방 및 치료용 조성물
PCT/KR2007/004833 WO2008041826A1 (en) 2006-10-02 2007-10-02 Novel benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof

Publications (1)

Publication Number Publication Date
MX2009002708A true MX2009002708A (es) 2009-07-27

Family

ID=39268649

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002708A MX2009002708A (es) 2006-10-02 2007-10-02 Nuevos derivados de tipo benzofurano, una composicion que comprende los mismos para tratar o prevenir la disfuncion cognitiva y el uso de los mismos.

Country Status (12)

Country Link
US (4) US8263649B2 (es)
EP (1) EP2069321B1 (es)
JP (1) JP5392776B2 (es)
KR (1) KR100858357B1 (es)
CN (1) CN101535285B (es)
AU (1) AU2007302941B2 (es)
BR (1) BRPI0715638A2 (es)
CA (1) CA2664857A1 (es)
IL (1) IL197758A (es)
MX (1) MX2009002708A (es)
NZ (1) NZ575538A (es)
WO (1) WO2008041826A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130111082A (ko) * 2012-03-30 2013-10-10 한미약품 주식회사 베타-아밀로이드 피브릴 형성 저해 효능을 갖는 아미노스티릴벤조퓨란 화합물 및 이를 함유하는 약학 조성물
WO2014007554A1 (en) * 2012-07-05 2014-01-09 Daewoong Pharmaceutical Co., Ltd. Method of preparing benzofuran derivative
US20160022625A1 (en) * 2013-03-06 2016-01-28 Jie Zheng Tashinones and their derivatives: novel excellent drugs for alzheimer disease
KR101499329B1 (ko) * 2013-06-17 2015-03-06 주식회사 대웅제약 (2-(3,4-다이메톡시페닐)-5-(3-메톡시프로필)벤조퓨란)의결정형 및 이의 제조방법
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
US10875833B2 (en) 2015-06-12 2020-12-29 Transitions Optical, Inc. Alignment compounds
WO2019113693A1 (en) * 2017-12-12 2019-06-20 Queen's University At Kingston Compounds and methods for inhibiting cyp26 enzymes
KR102191588B1 (ko) 2018-04-30 2020-12-15 아주대학교산학협력단 겐티아나 루테아 추출물 또는 이로부터 분리된 화합물을 유효성분으로 포함하는 인지 기능 장애 예방 또는 치료용 조성물
CN117756800A (zh) 2018-05-30 2024-03-26 普拉克西斯精密药物股份有限公司 离子通道调节剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2812664A1 (de) * 1978-03-22 1979-09-27 Plc Pharma Licences Verwendung von dilignolen und dilignolaehnlichen verbindungen als wirkstoffe von lebertherapeutica
JPS6053031B2 (ja) * 1978-03-31 1985-11-22 武田薬品工業株式会社 スピロ化合物およびその製造方法
US4863958A (en) * 1984-06-20 1989-09-05 Merck Frosst Canada, Inc. Benzofuran derivatives useful as inhibitors of mammalian leukotriene biosynthesis
WO1995017095A1 (en) * 1993-12-21 1995-06-29 Eli Lilly And Company Methods for the treatment or prevention of conditions associated with amyloidogenic reptides
GB9416219D0 (en) * 1994-08-11 1994-10-05 Karobio Ab Receptor ligands
US20040223912A1 (en) * 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
EP3067053A1 (en) * 2004-10-13 2016-09-14 PTC Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use

Also Published As

Publication number Publication date
CN101535285B (zh) 2012-09-26
CN101535285A (zh) 2009-09-16
IL197758A0 (en) 2009-12-24
EP2069321A4 (en) 2011-11-30
US20120245225A1 (en) 2012-09-27
IL197758A (en) 2013-07-31
EP2069321A1 (en) 2009-06-17
KR100858357B1 (ko) 2008-09-11
US8263649B2 (en) 2012-09-11
US8507553B2 (en) 2013-08-13
US20120259006A1 (en) 2012-10-11
US8455542B2 (en) 2013-06-04
AU2007302941B2 (en) 2012-11-15
BRPI0715638A2 (pt) 2013-07-02
EP2069321B1 (en) 2016-04-13
JP5392776B2 (ja) 2014-01-22
CA2664857A1 (en) 2008-04-10
NZ575538A (en) 2011-01-28
AU2007302941A1 (en) 2008-04-10
US8580848B2 (en) 2013-11-12
US20100197685A1 (en) 2010-08-05
US20120245165A1 (en) 2012-09-27
WO2008041826A1 (en) 2008-04-10
JP2010540407A (ja) 2010-12-24
KR20080030869A (ko) 2008-04-07

Similar Documents

Publication Publication Date Title
MX2009002708A (es) Nuevos derivados de tipo benzofurano, una composicion que comprende los mismos para tratar o prevenir la disfuncion cognitiva y el uso de los mismos.
TR201911199T4 (tr) Hücre büyümesini arttırmak için tedavi.
NZ631601A (en) Solid forms of a thiophosphoramidate nucleotide prodrug
WO2007134077A3 (en) 5 ht receptor mediated neurogenesis
WO2009017655A3 (en) Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof
GEP20135803B (en) Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
MX340490B (es) Derivados de pirazolo [1, 5a] pirimidina y de tieno [3, 2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
NZ598972A (en) Spiro-indoline-piperidine derivatives as selective GPR-40 activators for treating diabetes
SI2176252T1 (sl) 2,3-dihidrobenzo(1,4)dioksin-2-ilmetilni derivati kot alfa2C antagonisti za uporabo v zdravljenju bolezni perifernega in centralnega živčnega sistema
MX2012009073A (es) Derivados de 1, 2, 4-triazin-4-amina.
MA33776B1 (fr) Dérivés arylecarbonyle et hétéroarylcarbonyle d'hexahydroindénopyridine et d'octahydrobenzoquinoline
EA201201648A1 (ru) Стимуляторы sgc
IL210071A0 (en) Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
AU2008317057A8 (en) Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119
CL2010001159A1 (es) Compuestos derivados de 3,8-diazabiciclo[2.4.0]octano y 3,6-diazabiciclo[3.2.0]heptano disustituidos, moduladores del receptor de orexina; composicion farmaceutica; utiles en el tratamiento de trastornos del sueño, trastornos metabolicos, entre otros.
BRPI0818893B8 (pt) compostos de tropano, suas composições farmacêuticas, seus usos e método in vitro de inibição de hsp90 em uma célula
EA201201192A1 (ru) Тиенопиримидины, содержащие замещенную алкильную группу, предназначенные для фармацевтических композиций
TR201908514T4 (tr) İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇
NZ597075A (en) 1, 2, 4-thiazolidin-3-one derivatives as AMP-activated protein kinase (AMPK) agonists for treating cancer
MX2015003352A (es) Extracto de saliva entera de sanguijuela.
MX2009007436A (es) Derivados espirociclicos de acido tetronico.
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
MX2011005425A (es) Derivados de carboxiamida lantibiotica con actividad antibacteriana mejorada.
WO2010073104A3 (en) Improving cognitive function

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: MEDIFRON DBT CO., LTD.

FG Grant or registration